Mallinckrodt (MNK) Proxy filing summary

Executive summary

• The 2026 Annual General Meeting is scheduled for June 2, 2026, in Dublin, Ireland, with shareholders voting on key proposals including director elections, auditor re-appointment, executive compensation, capital reduction, and an amendment to the Articles of Association to facilitate a potential U.S. listing.

• Fiscal 2025 was transformational, marked by the merger with Endo, the spin-off of Par Health, and strong financial performance: $1.93 billion in net sales and $609 million in adjusted EBITDA.

• The company achieved $13 million in pre-tax merger synergies in Q4 2025 and targets $100 million in 2026, aiming for $150 million annual run-rate synergies by the merger's third anniversary.

• Acthar Gel and XIAFLEX delivered strong sales growth, and clinical programs for new indications are advancing, with key regulatory milestones expected in 2026.

Voting matters and shareholder proposals

• Shareholders will vote on nine director nominees, re-appointment of PricewaterhouseCoopers LLP as auditors, executive compensation (say-on-pay), frequency of future say-on-pay votes, reduction of company capital, and an amendment to the Articles of Association for DTC eligibility.

• Board recommends voting FOR all proposals and for annual say-on-pay votes.

• Special resolutions (capital reduction and Articles amendment) require a 75% majority.

Board of directors and corporate governance

• Board consists of nine directors, with a majority being independent; committee structure includes Audit, Governance and Compliance, and HRCC.

• Recent governance changes include amendments to the Articles of Association to facilitate the merger, spin-off, and potential NYSE listing, and updates to the Code of Conduct.

• Board leadership is currently separated between Chair and CEO, with plans for the CEO to become Chair by May 2026.

• Director nominations follow a rigorous process emphasizing diversity, independence, and relevant experience.